In the midst of the pandemic, Antibiotice doubled their investments
In 2020, a year affected by the pandemic with the SARS COV-2 virus, the Antibiotice company doubled its investments in research of new products, equipment for quality assurance, modernization of manufacturing technologies and digitalization of activities.
If in 2019, the value of investments in equipment was about 7 million lei, in 2020, Antibiotice doubled these investments, reaching over 14 million lei. This shows the company’s orientation both towards the prompt support of the national health system, through investments for the introduction in manufacturing of products used in COVID-19 therapy, and towards an accelerated sustainable development.
“Antibiotice must remain the most important pharmaceutical company with Romanian capital, and the maturity of the team, the guidance of the activities according to sustainable management plans and the strict observance of the operating procedures represent the guarantee of its sustainable development. Doubling turnover in the next period is a favorite target, and international expansion is certainly the most important step of the company’s shareholders. Of course, our goal is to increase the profitability of the business. We achieve this growth primarily through regular investment of profit in product development, applied research, sustainable partnerships, all the more so in this extremely difficult period for the entire business community around the world, “said Ioan Nani, CEO Antibiotice Iași.
The ambitious targets of Antibiotice Iași, until 2028, aim at doubling the turnover, the export, as well as obtaining a profit 2.5 times higher. Thus, in order to increase the competitiveness and profitability of the business, as well as to ensure long-term sustainable development, the company develops a coherent and continuous policy of development and strategic organization oriented on 5 pillars:
Pillar 1: Strategic adaptation of human resources
Pillar 2: Strategic adaptation of the product portfolio
Pillar 3: Continuous improvement of the Integrated Management System (quality, environment, health and safety at work)
Pillar 4: Strategic planning and performance management
Pillar 5: Corporate Governance
For the development of the strategic pillars and the implementation of the investment plans, year after year, Antibiotice received the approval from the shareholders for the financing, from the net profit, of the proposed investments.
Thus, in 2020 Antibiotice continued the investment policy according to the management plan approved by the General Meeting of Shareholders in April 2020, in the following directions: continuation of acquisitions for the construction of a new site for topical products – 14,452,190 lei – technological equipment and IT infrastructure
The new site will have a double production capacity and will increase the turnover by exposing these products both on the Romanian market and on the international markets. At the national level, the company holds the leading position in the production of topical products (ointments, gels and suppositories), research activity that supports the development of the product portfolio – 2,715,797 lei – product development projects
This activity is oriented towards those molecules valuable for patients’ health, which offer perspectives for consolidating the company’s basic portfolio (anti-infective, topical drugs), but also for specialized therapeutic classes (drugs for the treatment of chronic diseases, drugs for the Central Nervous System, drugs for Emergency Medicine). On the Romanian market, Antibiotice Iași is a leader in the production of anti-infective drugs.
At the same time, in order to support the international expansion of the business, Antibiotice Iași constantly adapts the formulas of the medicines in the portfolio to the registration requirements from other countries.
In 2020, the company invested in obtaining marketing authorizations and re-authorizations, for a number of 34 products for both the internal and external market (16 authorized products and 18 re-authorized products).
